Fatigue News and Research

RSS

Tai Chi may help overcome cognitive decline in patients receiving chemotherapy

According to the American Cancer Society, more than 11.4 million Americans are currently living with cancer. While cancer treatments are plentiful, many have negative side effects. Previous studies have indicated that a significant number of patients who receive chemotherapy also experience cognitive declines, including decreases in verbal fluency and memory.

7 Jun 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

Biogen Idec today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX dose titration, or gradual dose escalation, on flu-like symptoms associated with the therapy.

6 Jun 2011

Amylin's metreleptin clinical study data on partial lipodystrophy presented at ENDO 2011

Amylin Pharmaceuticals, Inc. today announced results from a study that showed treatment with metreleptin, an investigational treatment that is an analog of the human hormone leptin, improved diabetes and lipid control in patients with partial lipodystrophy.

6 Jun 2011

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

Following the conclusion of a series of meetings with the United States Food and Drug Administration (FDA), GTx, Inc. announced today the clinical trial design for the two Phase III Ostarine registration studies for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer (NSCLC).

6 Jun 2011

Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in advanced non-small cell lung cancer (NSCLC) that showed promising clinical activity in patients with progressive disease.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

6 Jun 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced efficacy and safety data from the BRIM3 trial, a large, randomized, multi-center Phase 3 clinical study of vemurafenib in patients with previously untreated metastatic melanoma with the BRAFV600 mutation.

6 Jun 2011

Ross River Fever vaccine trials begin

Australian researchers are working on a new vaccine that could protect against mosquito-borne Ross River Fever. They are conducting the world-first trial of the vaccine with positive results reported so far.

5 Jun 2011

MRSA found in cow’s milk

Scientists have discovered a new strain of the drug-resistant germ known as MRSA in cow’s milk and some evidence that the animals could be a source of the infection in humans.

5 Jun 2011

Five years after cancer treatment, many survivors still suffer symptoms

When people finish treatment for cancer, they want to bounce back to their former vital selves as quickly as possible. But a new Northwestern Medicine study -- one of the largest survivor studies ever conducted - shows many survivors still suffer moderate to severe problems with pain, fatigue, sleep, memory and concentration three to five years after treatment has ended.

4 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

Fatigue and poor health may have major impact on patients with functional dysphonia

Fatigue and poor health, anxiety and depression may have a major impact on patients with functional dysphonia (FD), leading to time off work, reduced activity, and social withdrawal, all of which could further perpetuate and/or cause anxiety, low mood, fatigue and reduced voice use, according to new research published in the June 2011 issue of Otolaryngology - Head and Neck Surgery.

2 Jun 2011

Cardiac resynchronization therapy improves sexual health in men with chronic heart failure

A new study published in the journal Clinical Cardiology reveals that in men with chronic heart failure, cardiac resynchronization therapy improves patients' libido, erectile dysfunction, and sexual performance.

2 Jun 2011

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Preliminary results of a Phase II single-arm study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's lenvatinib demonstrated an Objective Response Rate of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer.

1 Jun 2011

Scientists find no link between XMRV retrovirus and human disease

Delineation of the origin of the retrovirus known as XMRV from the genomes of laboratory mice indicates that the virus is unlikely to be responsible for either prostate cancer or chronic fatigue syndrome in humans, as has been widely published.

1 Jun 2011

Mouse virus not responsible for Chronic Fatigue Syndrome, new study finds

Two years ago, a widely publicized scientific report plucked an old mouse virus out of obscurity and held it up as a possible cause of Chronic Fatigue Syndrome. According to a new study published today by a group of researchers in California, Wisconsin and Illinois, that report was wrong.

1 Jun 2011

Nighttime heart and lung transplants do not affect patient survival

Despite concerns that surgeon fatigue is leading to dangerous complications for patients and data showing worse outcomes for many patients who undergo surgery at night, new Johns Hopkins research suggests that — in the case of heart and lung transplants — time of day has no affect on patient survival.

1 Jun 2011

Sleep loss reduces healthy young man's testosterone levels

Cutting back on sleep drastically reduces a healthy young man's testosterone levels, according to a study published in the June 1 issue of the Journal of the American Medical Association.

1 Jun 2011

Fatigue News and Research

Tai Chi may help overcome cognitive decline in patients receiving chemotherapy

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

Amylin's metreleptin clinical study data on partial lipodystrophy presented at ENDO 2011

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Ross River Fever vaccine trials begin

MRSA found in cow’s milk

Five years after cancer treatment, many survivors still suffer symptoms

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Fatigue and poor health may have major impact on patients with functional dysphonia

Cardiac resynchronization therapy improves sexual health in men with chronic heart failure

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Scientists find no link between XMRV retrovirus and human disease

Mouse virus not responsible for Chronic Fatigue Syndrome, new study finds

Nighttime heart and lung transplants do not affect patient survival

Sleep loss reduces healthy young man's testosterone levels

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News